Navigation Links
Nektar Therapeutics to Present at the 33rd Annual Cowen and Company Healthcare Conference in Boston
Date:3/1/2013

SAN FRANCISCO, March 1, 2013 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) Senior Vice President and Chief Medical Officer, Dr. Robert Medve , is scheduled to present at the 33rd Annual Cowen and Company Healthcare Conference at the Boston Marriott Copley Place on Tuesday, March 5, 2013 at 8:00 a.m. Eastern time.

The presentation will be accessible via a Webcast through a link posted on the Investor Relations, Events Calendar section of the Nektar website http://www.nektar.com. This webcast will be available for replay until April 8, 2013.

About Nektar

Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar has a robust R&D pipeline of potentially high-value therapeutics in pain, oncology and other therapeutic areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for naloxegol (NKTR-118), an investigational drug candidate, which has completed Phase 3 clinical development as a once- daily, oral tablet for the treatment of opioid-induced constipation. This agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of naloxegol and an opioid. In the proprietary pipeline, NKTR-181, a novel mu-opioid analgesic candidate for chronic pain conditions, is in Phase 2 development in osteoarthritis patients with chronic knee pain. NKTR-192, a novel mu-opioid analgesic in development to treat acute pain is in Phase 1 clinical development. In oncology, etirinotecan pegol (NKTR-102) is being evaluated in a Phase 3 clinical study (the BEACON study) for the treatment of metastatic breast cancer and is also in Phase 2 studies for the treatment of ovarian and colorectal cancers.

'/>"/>
SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
3. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York
4. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
5. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
6. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
7. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
8. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the UBS 2012 Global Life Sciences Conference in New York City
9. Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
10. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
11. Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... PLAINFIELD, N.J., Feb. 27, 2015  PTC Therapeutics, Inc. ... update and reported financial results for the fourth quarter ... "2014 was a transformative year for PTC. We ... delivering and developing RNA-targeted therapies in the rare disease ... PTC Therapeutics, Inc. "We are proud to bring the ...
(Date:2/27/2015)... , Feb. 27, 2015  Bionik Laboratories Corp. ... "Company"), announced today that it acquired Bionik Laboratories, Inc., ... and completed the sale to qualified accredited investors of ... aggregate gross proceeds of approximately $6.2 million. Shares of ... on the OTC Markets under the symbol "DWTPD" until ...
(Date:2/26/2015)... DALLAS , February 27, 2015 ... Review, H2 2014 market research report to its ... the Corneal Ulcers, therapeutic pipeline. The ... information on the therapeutic development for Corneal Ulcers. ... infections that includes bacterial infections, viral infections & ...
Breaking Medicine Technology:PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 10PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 11Bionik Laboratories Raises $6.2 Million 2Bionik Laboratories Raises $6.2 Million 3Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 2Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 3Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 4Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 5
(Date:2/28/2015)... 2015 National Sales Solutions ... marketing and supply chain management for consumer packaged ... bringing its award winning solutions for thinning-damaged hair ... are specifically created to combat thinning-damaged hair. ... committed to marrying science with nature to create ...
(Date:2/28/2015)... 2015 A case management conference ( ... have been filed by law firms including Bernstein Liebhard ... March, the Firm notes. , According to a ... the federal litigation will meet on March 13, 2015 ... therapy treatments designed to raise levels of the male ...
(Date:2/28/2015)... On Thursday, February 26th, Forbes published an article titled ... Steal Your Data , which stresses the ease with which ... phishing kit, or any kind of malware kit for that ... about how everyone’s cyber security is intertwined when it covers ... content management systems or blogs in order to install the ...
(Date:2/28/2015)... California (PRWEB) February 28, 2015 Developers of ... release of a new overlay plugin for Final Cut Pro ... Studios. , “FCPX Overlay Chromatic gives users total control over ... Christina Austin, CEO of Pixel Film Studios. “FCPX Overlay Chromatic ... an easy to use interface.” , FCPX Overlay Chromatic Grunge ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 Plugin creators ... TransFold Volume 2. A fully customizable transition ... “TransFold Volume 2 gives users total control over 30 ... Austin, CEO of Pixel Film Studios. “TransFold Volume 2 ... editor.” , TransFold Volume 2 from Pixel Film Studios ...
Breaking Medicine News(10 mins):Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 3Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 2Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 3Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 4Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 2Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 3Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 4Health News:Pixel Film Studios released a new overlay plugin entitled FCPX Overlay Chromatic Grunge 6K exclusively for Final Cut Pro X users 2Health News:Announcing a New TransFold Transition Pack from Pixel Film Studios for Final Cut Pro X Professionals 2
... series of wireless High Definition video communication products ... achieve considerable cost savings and efficiency improvements. These ... economic climate, where the impact of recession and ... product is capable of virtually eliminating the need ...
... dendritic cells act as the security alarms of the ... cells can transmit the alarm to white blood cells ... they send out. , Researchers at the Emory ... discovered that dendritic cells can respond to the same ...
... difficult negotiation tactics their prospects and customers use, if they ... the professional educational forum for sales process improvement hosts a ... firm to demonstrate a sales negotiation approach that increases sales ... ...
... to severe dog bites in the head and neck areas, ... and rising temperatures, according to new research published in the ... , In an evaluation of 84 cases of dog bites ... most injuries were caused by family pets (27%), with a ...
... extracted from green vegetables such as broccoli and ... according to cancer researchers. Tests on mice suggest ... tumors more safely and effectively than conventional therapy. ... the proteins that trigger melanoma," said Gavin Robertson, ...
... Schweitzer (Chair of the Democratic Governors Association) and Maryland ... applauded President Obama,s reported selection of former DGA Chair ... Services. "Our health care system is broken, and Governor ... effort to fix it," Governor Schweitzer said. "In reforming ...
Cached Medicine News:Health News:Pixavi Releases Recession Proof Technology 2Health News:Pixavi Releases Recession Proof Technology 3Health News:Pixavi Releases Recession Proof Technology 4Health News:Pixavi Releases Recession Proof Technology 5Health News:Vitamin A signals offer clues to treating autoimmunity 2Health News:How to Increase Sales Margin 1 Percent to 10 Percent and Lower Your Risk by Building a Negotiation Strategy into Your Sales Process 2Health News:How to Increase Sales Margin 1 Percent to 10 Percent and Lower Your Risk by Building a Negotiation Strategy into Your Sales Process 3Health News:Dog bites a particular threat to young children, especially as temperatures rise 2Health News:Vegetable-based drug could inhibit melanoma 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: